- Conditions
- Hydrocephalus in Infants, Hydrocephalus Acquired
- Interventions
- Sulfur Hexafluoride Lipid Type A Microspheres 25 mg Injection Powder for Suspension [LUMASON]
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 1 Minute to 18 Months
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced May 22, 2026, 12:10 AM EDT